- "Ivermectin-much-more-than-you-wanted to Know," by Scott Alexander, the very best thing on the Ivermectin studies that I've seen as of November 2021.
- David Friedman on Ivermectin and not finding that India has approved its use on a massive scale.
- "Lastly, what I found interesting and troubling was the removal of 30years of publications from PubMed, Lancet, NewEnglandJournal etc. regarding the use of treatments, which I had previously read as I had made investments in my former life in Biotech VC into a company overlapping into the Quinine/Chloroquine/Hydrochloroquine space and another which I sold to Sanofi which used Ivermectin in high concentration in hair cream (suspended in olive oil) for the highly effective treatment of lice (it’ll kill the eggs too) and we researched the hell out of both of these meds, as the use case included the once heralded pediatrics space (5-12 year olds) where the hippocratic oath was taken very seriously. Beyond the removal of the Meds, the barring of their use by knowledgable physicians and their patients using the physicians regulatory bodies, and the barring of filling scrips by the pharmacy regulatory groups and associations.
The reason we are not seeing treatment cocktails in wide spread use, IMHO, is that they’ve tried like hell to shut down their experimentation and the use of the ones which had been considered generally positively impactful. Again I will ask, why is this the case?
Oh and before immediately go to ’the studies’ look more deeply at the trial design where they took these early use med packs (they work at reducing viral replication giving the immune system a better chance to take it out) and used them on very late stage viral loads and said ’see they don’t work’ …… well maybe not at that stage they don’t but were they studies designed to fail but you could also look at their effective use in large countries such as India with high quality impacts. " (2021, NOvember)
- "Update on ivermectin for covid-19," Sebastian Rushworth (April 2021).
There is one thing that is rather odd with this study, and that is that the study authors were receiving payments from Sanofi-Pasteur, Glaxo-Smith-Kline, Janssen, Merck, and Gilead while conducting the study. Gilead makes remdesivir. Merck is developing two expensive new drugs to treat covid-19. Janssen, Glaxo-Smith-Kline, and Sanofi-Pasteur are all developers of covid vaccines. In other words, the authors of the study were receiving funding from companies that own drugs that are direct competitors to ivermectin. One might call this a conflict of interest, and wonder whether the goal of the study was to show a lack of benefit. It’s definitely a little bit suspicious...
This study is yet another one of those many studies that will not be able to show a meaningful effect on hard end points like hospitalization and death. It is a bit strange that studies keep being done on young healthy people who are at virtually zero risk from covid-19, rather than on the multi-morbid elderly, who are the ones we actually need an effective treatment for.